Roche CEO Thomas Schinecker said in a statement on Tuesday that the company’s new $50 billion investment demonstrated its ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with severe COVID-19 pneumonia, following independent research in China suggesting it may help ...

JERSEY CITY, N.J., April 01, 2025--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. JERSEY CITY ...

On April 17, 2025, the Supreme Court resolved a circuit split on the appropriate pleading standard for a specific type of prohibited transaction ...

Jennifer Demba; Investor Relations; Synovus Financial Corp. Kevin Blair; Chairman of the Board, President, Chief Executive Officer; Synovus Financial Corp. Andrew ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: 17 April at 16:00:02 GMT-4 ...

Biogen Inc. and Genentech Inc. are heading to trial in June over a significant contract dispute concerning patent royalties ...